
BioMarin Pharmaceutical (BMRN) P/E Ratio
P/E Ratio as of Jul 2, 2025: 21.21
Average20.71
Median20.82
Minimum20.07
Maximum21.33
21.21
Past Month+0.04 (0.19%)
The P/E ratio for BioMarin Pharmaceutical (BMRN) is 21.21 as of Jul 2, 2025. This represents a decrease of -46.59% compared to its 12-month average P/E ratio of 39.71. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
BioMarin Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
BioMarin Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing BioMarin Pharmaceutical to industry peers.
BioMarin Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
BioMarin Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing BioMarin Pharmaceutical to industry peers.
BioMarin Pharmaceutical (BMRN) P/E Ratio Insights
See BioMarin Pharmaceutical’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in BioMarin Pharmaceutical (BMRN)
Order type
Buy in
Order amount
Est. shares
0 shares
BioMarin Pharmaceutical (BMRN) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $56.19 | 20.85 |
Jun 2, 2025 | $57.05 | 21.17 |
May 1, 2025 | $62.71 | 28.51 |
Apr 1, 2025 | $67.94 | 30.89 |
Mar 3, 2025 | $71.02 | 32.29 |
Feb 3, 2025 | $62.44 | 37.60 |
Jan 2, 2025 | $66.49 | 40.03 |
BioMarin Pharmaceutical (BMRN) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | 21.21 | -46.41% |
2024 | 39.58 | -68.65% |
2023 | 126.25 | -49.24% |
2022 | 248.71 | -198.69% |
2021 | -252.00 | -1,350.00% |
2020 | 20.16 | — |
FAQs About BioMarin Pharmaceutical (BMRN) P/E ratio
The latest P/E ratio of BioMarin Pharmaceutical (BMRN) is 21.21, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
BioMarin Pharmaceutical’s last 12-month average P/E ratio is 39.71, compared to its current P/E ratio of 21.21. This reflects a decrease of -46.59%.
BioMarin Pharmaceutical’s current P/E ratio of 21.21 is lower than its last 12-month average P/E of 39.71. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
BioMarin Pharmaceutical’s average P/E ratio over the last 3 years is 125.07. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
BioMarin Pharmaceutical’s average P/E ratio over the last 5 years is 233.84. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.